April 7, 2025 4:51pm
Symbolizes or about an enslaved country desiring freedom from a tax/tariff levied by governments other than ours
We fought-back once over tea and repression winning the Revolutionary War
While I’m hoping for a recession in economic data
News: BioLife Solutions (BLFS +$1.06) acquired privately-held PanTHERA CryoSolutions, Inc., a developer of novel cryopreservation solutions based on proprietary Ice Recrystallization Inhibitor ("IRI") technology. The acquisition further strengthens its position as a market leader in bio-preservation, enhancing its product portfolio of consumable solutions and adds scientific capabilities.
I say today what others won't, so you can do what others can't!
Never leave an investor uninformed!
On point, short on words, long on facts and being judicious!
My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets. I put hours of effort to create reporting, while leveraging my 40 years of operating and research experiences to analyze the key market-moving events and distill that into a cogent outlook.
Monday’s RegMed Investors’ (RMi) pre-open: could the dead cat bounce begin? … https://www.regmedinvestors.com/articles/13869
Friday night’s RegMed Investors (RMi) Closing Bell: another fall to newer bottoms … https://www.regmedinvestors.com/articles/13868
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), formerly Biostage (OTCQB: HRGN) The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812
Monday: The Dow closed DOWN -349.26 points or -0.91%, the S&P closed DOWN -11.83 points or -0.23% while the Nasdaq close UP +15.48 points or +0.10%
- U.S. stocks bounced between gains and losses in a volatile trading session Monday
Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies
- Fears grew that the sell-off would feed on itself with hedge funds forced to sell down equities and other risky assets to raise cash needed meet margin calls. The CBOE Volatility Index (VIX) the fear gauge, surged to the 50 level today, an extreme level seen mostly only during bear markets.
Monday’s advance/decline line opened with a negative 1 incliner, 32 decliners and 2 flats ending with a negative close of 13 incliners, 20 decliners and 2 flats
- Don’t SELL as any rebound has yet to overcome obstacles but not the sense of hope as volatility continues to spike while markets lead the sector
Metrics: Monday, the IBB was down -0.95%, the XBI was down -0.67% while the VIX was up +1.67 points or +3.69% at 46.08
Q2/24 -April – 1 positive and 4 negative closes
- Q1/25 – March, 10 positive and 12 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Monday’s Closing UP (13 of 13)
- Ionis Pharmaceuticals (IONS +$0.48 after Friday’s -$1.43),
- Moderna (MRNA +$0.53)
- BioLife Solutions (BLFS +$1.06 after Friday’s -$1.56) with acquisition
- AxoGen (AXGN +$0-.40 after Friday’s -$0.82),
- Agenus (AGEN +$0.28),
- Fate Therapeutics (FATE +$0.1565),
- Compass Therapeutics (CMPX +$0.11),
- Precigen (PGEN +$0.09),
- Sangamo Therapeutics (SGMO +$0.0504 after Friday’s +$0.0342)
- MiMedx (MDXG +$0.03),
- Beam Therapeutics (BEAM +$0.13 after Friday’s -$1.19
- Cellectis SA (CLLS -$0.01),
- Generation Bio (GBIO +$0.0029),
Flat (2)
- Harvard Apparatus RT (OTCQB: HRGN)
- Homology Medicine (FIXX)
Monday’s Closing DOWN (10 of 20):
- Alnylam Pharmaceuticals (ALNY -$2.79 after Friday’s -$26.42),
- Vericel (VCEL -$2.02 after Friday’s -$1.57
- Lenz Therapeutics (LENZ -$1.68 after Friday’s -$1.82
- Blueprint Medicine (BPMC -$1.488 after Friday’s -$5.43),
- Regenxbio (RGNX -$0.36),
- Ultragenyx Pharmaceuticals (RARE -$0.29 after Friday’s -$2.70),
- Verve Therapeutics (VERV -$0.28),
- CRISPR Therapeutics (CRSP -$0.27),
- Adverum Biotechnologies (ADVM -$0.23),
- Sage Therapeutics (SAGE -$0.20),
As compared to… Friday: The Dow closed DOWN -2,231.07 points or -5.50%, the S&P closed DOWN -322.44 points or -5.97% while the Nasdaq closed DOWN -962.82 points or -5.82%
- Another pounding Friday after China retaliated with new (34% levy on all U.S. product) tariffs
Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies
- U.S. payrolls rose by 228,000 in March, but unemployment rate increases to 4.2%. Health care was the leading growth area, consistent with prior months. The industry added 54,000 jobs, almost exactly in line with its 12-month average. While, average hourly earnings increased 0.3% on the month, in line with the forecast, while the annual rate of 3.8%, the lowest level since July 2024.
Friday’s advance/decline line opened with a negative 3 incliner, 30 decliners and 2 flats ending with a negative close of 3 incliners, 30 decliners and 2 flats
Metrics: Friday, the IBB was down -6.63%, the XBI was down -4.48% while the VIX was up +14.20 points or +47.32% at 44.22
The BOTTOM LINE: For the four (4) past sessions (from last Wednesday), President Trump's tariff announcement has sparked a major sell-off in the US stock market leaving many investors unsure of how to proceed.
I STILL think the sell-off is overdone but, no one can argue with the ongoing results ...
- As I stated, I saw the beginning of “bottom feeding” yesterday of the undervalued and oversold? – Yes!
The Russell 2000, the small-cap index fell to lows last seen in late 2023.
- The Russell 2000 slid nearly 2% in midday trading. At session lows, the index hit levels that it hasn’t dropped to since November 2023.
- Monday’s declines mark the latest sign of trouble for the index, which officially entered bear market territory last week. That’s a sharp turn, given the Russell 2000 had rallied in November with traders expecting small-caps to benefit from Trump’s preference for deregulation.
- The index has tumbled more than 10% over the last 5 trading days, bringing its year-to-date loss to more than 19%. <CNBC>
Overwhelmingly negative breadth during 4-day rout …
- Few stocks have managed to see any gains during the post-tariff announcement rout over the past 4 trading sessions.
- About 2/3’s of both the S&P 500 and Nasdaq 100 are down 10% or more. <CNBC>
“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
- If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
I don’t have much to write/say other than “electronic trading and uncle algo” slipped out the back door reaping sector disharmony and then popped right back for some profiteering.
- What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.” <me>
April ‘25: understand the “flow” …
- 4/7 - Monday closed negative with 13 positive, 20 negative and 2 flats
- 4/4 – Friday closed negative with 3 positive, 30 negative and 2 flats
- 4/3 – Thursday closed negative with 2 positive, 32 negative and 1 flat
- 4/2 - Wednesday closed positive with 9 positive, 25 negative and 1 flat
- 4/1 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
Big Point to remember “Think about it; the biggest problem the cell and gene therapy sector it’s all to the future … 99% of them have no earnings!
- “Stock selloff puts M&A and IPOs worth Billions on hold” … for cheaper prices in M&A but questionable pricing for offerings, that are desperately needed financings.
What could 2025 have in store for the capital access space?
- "You'll see a number of cell and gene therapy companies drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in pipelines … capital expansion is second.
Why do I keep repeating, so investors can make the connection …
The top three (3) performing in the session:
- Monday: BioLife Solutions (BLFS), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)
- Friday: Fate Therapeutics (FATE), bluebird bio (BLUE) and Sangamo Therapeutics (SGMO)
The worst three (3) in the session:
- Monday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Lenz Therapeutics (LENZ)
- Friday: Alnylam Pharmaceuticals (ALNY), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
